Jan 15 (Reuters) - AbbVie ( ABBV ) will commit less capital towards experimental
medicines for psychiatric disease, CEO Robert Michael said at an industry conference on
Wednesday.
The remarks come months after experimental schizophrenia drug failed in two mid-stage
studies.